PTPRC and neoplasm: The dataset included tumor-infiltrating CD45+ immune cells isolated from 40 patients: 14 newly diagnosed GBM (GBM.new), 12 recurrent GBM without prior immunotherapy (GBM.rec), and 14 recurrent GBM with neo-aPD-1 therapy (GBM.pembro; n  =  156,766 cells in total; ref. 60).